Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Epigenetics Market to Surpass US $35.84 Billion by 2031, Fuelled by Rising Prevalence of Cancer - Latest Industry Research by The Insight Partners

globenewswire.com
ILMN Illumina is mentioned as a major global supplier of kits and reagents for epigenetic analysis, which are crucial for research and diagnostics in areas like oncology and personalized medicine, suggesting a positive market position. TMO Thermo Fisher Scientific is listed as a major global supplier of kits and reagents for epigenetic analysis. These products are essential for research and diagnostics, particularly in oncology and personalized medicine, indicating a positive market role.

Epigenetics Market to Surpass US $35.84 Billion by 2031, Fuelled by Rising Prevalence of Cancer - Latest Industry Research by The Insight Partners New York - NY, March 11, 2026 (GLOBE NEWSWIRE) -- A new comprehensive market research report, published by The Insight Partners, reveals that the Global Epigenetics Market is projected to grow from US$ 11.12 billion in 2024 to US$ 35.84 billion by 2031, registering a CAGR of 18.3% during the forecast period from 2025 to 2031.

Market Growth Highlights:

To explore the valuable insights in the Epigenetics Market report, you can easily download a sample PDF of the report - https://www.theinsightpartners.com/sample/TIPHE100000971

The level of output in epigenetic research remains among the highest globally, with more than 6,300 articles by US-based researchers indexed in PubMed and accounting for over 46% of all academic publications worldwide. Many grants provided by government agencies are valued in the millions of dollars, and hundreds of ongoing clinical studies are evaluating the efficacy of epigenetic therapeutics, including HDAC inhibitors for both solid tumors and hematologic cancers.

Currently, there are more than 57 companies in the US dedicated to epigenetics, including Chroma Medicine, Syros Pharmaceuticals, EpigenCare, and Fulcrum Therapeutics. Academia and industry collaborate to support translational research and core facilities, spanning basic science through the development of diagnostic and therapeutic products, which has made the US one of the leading international centers for epigenetic development.

Market is Driven by Biomarker and Diagnostic Development:

Methylation-driven biomarkers and noninvasive tests, which help identify illnesses and provide options for early diagnosis and tailored treatments, have driven the rapid growth of the epigenetic market. Blood-based tests, such as Epi proColon and Cologuard for colorectal cancer, and ThyraMIR and ThyGenX for thyroid cancer, provide high levels of sensitivity and specificity in detecting cancer. Moreover, MGMT methylation and cfDNA profiling contribute to tumor detection and monitoring recurrence, as well as improved accuracy for indeterminate nodules. In cardiovascular disease risk prediction, multilocus EpiScores provide superior prediction of cardiovascular risks compared to traditional methods. Finally, advanced technologies such as pyrosequencing, MethyLight, MS-HRM, and next-generation sequencing can detect methylation with high sensitivity, and new point-of-care devices provide additional applications across oncology and chronic disease management.

Download Sample PDF @ https://www.theinsightpartners.com/sample/TIPHE100000971

Major Epigenetics Companies Include:

Epigenetics Market Segmentation Analysis:

Services Segment to Grow at Highest CAGR

Epigenetic services involve sequencing, data analysis, and consulting from an expert who utilizes ChIP-seq, bisulfite sequencing, and DNA methylation profiling. The methodology and interpretation of data are complex, and scientists depend on specialized providers to perform accurate high-throughput analyses. BGI Genomics provides extensive analyses of whole-genome bisulfite sequencing to identify methylated cytosines and cancer biomarkers. The business model is based on pay-per-project, allowing biotech companies and research institutions to access innovative technology and expert knowledge without the need to invest in costly infrastructure themselves.

Kits and Reagents to Hold the Largest Market Share

Reagents and kits enable accurate analysis of DNA methylation, histone modification, chromatin remodelling, and gene expression to be performed for research and diagnostics. Kits such as bisulfite conversion kits, ChIP sequencing kits, and specific antibodies enable a variety of uses in areas including oncology, neurology, and personalised medicine. Some of the largest global suppliers of kits and reagents include QIAGEN, Thermo Fisher Scientific, Illumina, and Abcam. In addition, several domestic suppliers have gained traction as they provide lower prices, faster shipping, and pose less risk from tariffs and supply chain issues.

Asia Pacific region to Witness Fastest Growth:

Asia Pacific is expected to record the fastest growth in the global Epigenetics Market during the forecast period. This growth is supported by:

The epigenetics market in Asia Pacific is registering the highest growth rate, owing to the extensive academic research and government support in China, Japan, Australia, and India. This region has produced a large number of academic publications on cancer (cancer EP genes) and metabolic-EG (M-EG) genes, appearing in over 58,000 articles indexed in PubMed. Novel discoveries such as chidamide (an HDAC inhibitor), 3D epigenome mapping, and single-cell profiling are taking place within the region. Significant support from funding agencies and the presence of a diverse population allow for the study of unique environmental and age-related factors. Additionally, expanding clinical trial activity strengthens the impact of Asia Pacific on the development of therapeutic methods and diagnostic tests using epigenetics.

Epigenetics Market Dynamics:

Driver: Advancements in Epigenetic Technologies

Innovations in epigenetic technologies will help propel the market growth by allowing for fast regulation of genes without changing their DNA sequences. For example, the use of CRISPR-dCas9 as an epigenome editor will allow researchers to reactivate genes and suppress tumors at a very high level of efficiency, even in preclinical studies. Additionally, improvements in single-cell sequencing technologies will further increase resolution and throughput. The use of AI to improve the accuracy of CRISPR is also expanding the number of clinical trials for the treatment of cancers and genetic disorders. Emerging technologies—including UHRF1 inhibitors, mRNA-based editors, and multiomics integration—will create new opportunities for researchers to find potential new therapeutic targets. The growing number of published research and ongoing late-phase clinical trials highlights the emerging importance of epigenetics in precision and regenerative medicine.

Opportunity: Growth in Lifestyle and Environmental Health Initiatives

Changes in lifestyle and environment can influence how genes express and help cope with disease while promoting optimum health through changes in the epigenome. Foods in the Mediterranean diet or a ketogenic diet, as well as physical activity and mindfulness practices, have been shown to create changes in DNA methylation, leading to better metabolism, less inflammation, and a younger bio-age. In addition to lifestyle interventions, maternal influences and the environment can influence the establishment of epigenetic marks and can affect future generations. The information gathered by researchers about 900 different exposome associations informs many public health initiatives, such as vitamin supplementation, and programs that utilize personalized multiomics data and AI to provide lifestyle predictive interventions. The continued momentum of nutrigenomics, wellness applications, and preventive healthcare is expected to fuel this trend.

Challenge: High Development and Implementation Costs

High costs of developing and implementing epigenetics solutions limit the ability to access and scale these solutions. Advanced diagnostics technologies—such as NGS and mass spec—and the drug development processes require significant investments and clinical utility, which requires specialized training and facilities. Although there are opportunities for significant long-term savings—such as reductions in hospitalizations—high up-front costs and regulatory challenges limit the ability of these solutions to support innovation and provide equitable access.

Purchase Premium Copy of Global Epigenetics Market Size and Growth Report (2025-2031) at: https://www.theinsightpartners.com/buy/TIPRE00042178

Recent Developments:

About The Insight Partners

The Insight Partners is a global market research and consulting firm delivering in-depth analysis and actionable insights across technology, media, telecommunications, healthcare, and industrial sectors. The firm supports organizations in identifying growth opportunities, understanding market dynamics, and making informed strategic decisions.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Ankit Mathur

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

Press Release - https://www.theinsightpartners.com/pr/epigenetics-market

Related Reports: